key: cord-0815156-8fu0wwzn
authors: Fusco, Flavia; Scognamiglio, Giancarlo; Merola, Assunta; Roma, Anna Selvaggia; Nicastro, Carmine; Spatarella, Micaela; D'Abbraccio, Maurizio; Di Mauro, Gabriella; Atripaldi, Umberto; Atripaldi, Lidia; Correra, Anna; Palma, Michela; Barracano, Rosaria; Borrelli, Nunzia; Capuano, Annalisa; Sarubbi, Berardo
title: COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre
date: 2021-10-28
journal: Int J Cardiol Congenit Heart Dis
DOI: 10.1016/j.ijcchd.2021.100266
sha: 2b6ad45b96dffab0b21a0e19cf757bbe82662285
doc_id: 815156
cord_uid: 8fu0wwzn

Background real-world data on COVID-19 vaccine safety, immunogenicity and acceptance in adults with congenital heart disease (ACHD) are lacking. Methods ACHD patients who were offered COVID-19 vaccination from January to June 2021 were included. Data on adverse events, on patients’ attitude towards vaccination and antispike IgG titre were retrospectively collected. A group of healthy individuals with similar age and sex undergoing vaccination was included for comparison. Results 208 patients followed in a single ACHD tertiary centre (33.3 [26–45]years,54%male) received COVID-19 vaccine, 65% vaccinated at our institution: 199 (96%)received Pfizer–BioNTech BNT162b2 vaccine, 4 (2%)Moderna-1273 and 5 (2%)AstraZeneca–ChAdOx1. Median follow-up after vaccination was 79 [57–96]days. No major adverse event was reported and there was no difference in the in adverse events incidence between ACHD patients and the control group. One patient was diagnosed with acute pericarditis. There were two unrelated deaths during follow-up. Three (1.5%)vaccinated patients tested positive for COVID-19. Antispike IgG titre, available in 159 (76%)patients, was 1334 [600–3401]BAU/ml, not significantly different from the control group (p = 0.2). One patient with Fontan failure was seronegative. Advanced physiological stage was related to lower antibody response, independently from previous viral exposure (p < 0.0001). Fourteen percent refused COVID-19 vaccination at our institution. However, 50% of vaccinated patients declared to have been influenced by the discussion with the ACHD cardiologist and 66% of those vaccinated in situ reported that undergoing COVID-19 vaccination at the ACHD centre made they feel safer. Conclusion COVID-19 vaccines appear safe in ACHD with satisfactory immunogenicity. However, most vulnerable patients showed lower antibody response. ACHD team may have a key role in vaccine acceptance.

Coronavirus disease-2019(COVID- 19) has had a devastating impact worldwide, claiming nearly 4million victims as of June 2021 1 . Universal COVID-19 vaccination will be the keystone in the fight against the pandemic. Patients with cardiovascular disease 2 , including adults with congenital heart defects(ACHD), bear a higher risk of adverse outcome in case of infection, and it has been suggested that they should be prioritized by vaccine allocation policies 3 . Although the approval trials of most recently licensed vaccines have shown good safety profile with high efficacy 4, 5 , real-world data are still lacking. Thus, patients with underlying heart disease may opt out of vaccination, fearing adverse cardiac effects from doing so.

The Italian Government launched a nationwide vaccination campaign started on December 31,2020: vaccines were offered to the entire population according to a priority order, accounting for vaccines availability and individual vulnerability to COVID-19. In particular, healthcare and education workers, residents of long-term care facilities and vulnerable subjects, defined as patients>80years, in NYHA class III-IV and those with genetic syndromes were initially targeted 6 and invited to undergo COVID-19 vaccine at local health districts.

With the present study, we aimed to describe the current state of COVID-19 vaccination among ACHD patients followed at our tertiary centre, investigating vaccine safety, immunogenicity and patients' attitude towards vaccination in this complex population.

From March 17,2021, vulnerable ACHDpatients followed at our tertiary ACHD centre and not yet vaccinated locally were offered mRNA-based COVID-19 vaccines in a dedicated unit with specialized personnel and availability of anaesthesiologists and cardiologists experienced in ACHD care. In addition to the subjects meeting the national "vulnerability"criteria, patients with the following characteristics were prioritized at our centre: univentricular physiology, systemic right J o u r n a l P r e -p r o o f ventricle, ejection fraction<40%, severe valvular defects and ventricular dilation/dysfunction or awaiting cardiac surgery. In agreement to local guidelines, the second dose was not administrated to those with previous severe acute respiratory syndrome coronavirus2(SARS-CoV-2)infection adequate response at 3weeks and those with SARS-CoV-2 infection in the last 3months 8 . Patients with previous history of any allergies were pre-treated with antihistaminic and corticosteroids.

Patients undergoing COVID-19 vaccination were invited to contact the ACHD team in case of symptoms following COVID-19 vaccination and were instructed to fill in the adverse event report form, according to the European legislation 7 . Blood samples were routinely obtained 3 weeks following the last dose in order to quantify the antibody response in this population and determine previous viral exposure.

Consecutive ACHD patients aged≥16years who were offered COVID-19 vaccine either at our institution or locally between January and June 2021 were included. Demographic data, data on previous medical history, vaccine type, side effects, antibody titre and general attitude towards COVID-19 vaccines were retrospectively collected from patients' electronic records. A group of healthy volunteers with similar age and sex who underwent COVID-19 vaccination was enrolled among the health personal working at our Institution as a control. Informed consent was obtained from each patient before study inclusion. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institutional ethics committee.

All analytical procedures were performed at the Department for Laboratory Medicine, Monaldi

Hospital. Sera were stored at 2-10°C for <2days within the Monaldi Hospital facility for the storage of biomaterial with certified quality management(ISO9001:2015).CE-marked Roche Elecsys®Anti-SARS-CoV-2 Sbinding assay was used. This is an electrochemiluminescence sandwich immunoassay J o u r n a l P r e -p r o o f which allows to obtain both qualitative detection of SARS-CoV-2 antibodies against the nucleocapsid antigen(indicating previous exposure to SARS-COV2)and quantitative detection of antibodies directed against the viral spike protein. The manufacturer states intra-and interassay precision of 1-3% and positive agreement with a virus pseudo-neutralization assay of 92%(95%CI64-100%) with a specificity of 99.98%(95%CI99.91-100%). The quantification range is between 1 and 12500BAU/mL.Results≥1BAU/mL were considered positive, while a titre<100BAU/mL was considered as poor antibody response.

Statistical analysis was carried out using Rversion4.0.5. Continuous variables were reported as mean±SD or median[IQR],according to data distribution. Comparisons between groups were assessed with the Student t-test or with Wilcoxon rank-sum test. Categorical variables were presented as frequencies(percentage of total). Differences in proportions were evaluated with χ 2 . Univariate and multivariable linear regression model was derived with the Spearman method using the log of IgG values as the dependent variable. Variables significant on univariate analysis were included in the multivariable model. P-value<0.05 was considered statistically significant.

As of June 2021,208 ACHD patients received COVID-19 vaccine: 73(35%) locally and 135(65%) at our institution. One-hundred and ninety-eight(95%) received 2 doses according to vaccination schedule and 10 out of 15 patients with previous SARS-COV2 infection received only the first dose. Two fully vaccinated patients and one with the first vaccine dose were tested positive for COVID-19:they reported only mild symptoms and, in the latter case, the second dose was not administrated.

The median follow-up after vaccination completion was 79[57-96]days. Participants reported symptoms after the first and second dose in 78 and 37% of cases, respectively. However, symptoms duration was always limited. Post-vaccination symptoms are summarized in Table2 

Antispike IgG titre after a median of 25 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] 

Overall,157 ACHD patients were offered COVID-19 vaccination at our institution. Twenty-two of them(14%) refused the vaccine even after discussion with the ACHD team (clinical details are summarized in Table5). Patients rejecting the vaccination had similar age(p=0.8), sex(p=0.5), and disease complexity(p=0.08) compared with the study population. Data on vaccine attitude were available for 163(78%) out of 208 vaccinated patients: 28% appeared to have concerns regarding vaccine safety before discussing it with their general practitioner or cardiologist, 30% reported being scared of potential effects of the vaccine on their cardiac disease and 50% were at least partially influenced by the discussion with their ACHD cardiologist in their decision to undergo COVID-19 vaccination. Sixty-six percent of those vaccinated in situ declared that undergoing vaccine at the ACHD centre made they feel safer.

with Pfizer-BioNTech BNT162b2 mRNA vaccine were enrolled. The control group was not significantly different from the study population for age and sex(31[34-58]years,54% male, p=0.6 and 0.8 respectively). Controls showed similar prevalence of symptoms after the first dose of vaccine compared with ACHD patients (50=68% vs 75%,p=0.2). However, a higher proportion of controls complained of symptoms following the second dose (58=78% vs 50%,p=0.0001). Anti-spike titre measured at 27 [23] [24] [25] [26] [27] [28] [29] [30] 

Certain ACHD patients bear an increased risk of death from COVID-19. An international multicentre study including 1044 infected ACHD patients showed that cyanosis, pulmonary hypertension, renal failure, physiological stage and previous hospital admission for heart failure were associated with the risk of death 9 . Accordingly, several scientific statements recommended to prioritize ACHD patients J o u r n a l P r e -p r o o f in the vaccine allocation strategy 3,10.,11 . However, the current approach to COVID-19 vaccination inACHD patients is mainly based on the vaccines trial data. Herein, we report the first results of an observational study conducted at an ACHD tertiary centre during the COVID-19 pandemic demonstrating the safety and immunogenicity of COVID-19 vaccines in this complex population.

Our results provided reassuring data for a good safety profile of the vaccines, with most adverse events being transient and mild, similarly to what has been previously reported in the general population 12 Another emerging concern is the risk of thrombotic events 15, 16 , especially in ACHD patients who are already prone to their occurrence. Despite the absence of such events in our cohort, no definite conclusions should be drawn based on our data, as only a minority of patients received adenovirus-based vaccines which have been associated with thrombotic risk 19, 20 .

Other rare adverse events were limited in number, required medical treatment in a small proportion of cases and did not seem to have relevant consequences. However, considering that the vast majority of patients in our cohort received a Pfizer-BioNTech BNT162b2 mRNA vaccine, the safety data herewith reported should be mainly attributed to this type of vaccine.

Most ACHD patients in our study showed a satisfactory response with a median antispike titre comparable to the control group. Only 1 seronegative case was demonstrated at 3 weeks from the second dose in a patient with Fontan failure. Other complex ACHD patients showed a flat antibody response in 3% of tested cases. Similarly to what has been reported in the general population 17, 18 , ACHD patients with COVID-19 pre-existing immunity developed a higher antibody response.

Moreover, our results suggested that most vulnerable ACHD patients may develop lower anti-spike IgG titre, regardless of previous viral exposure. As in our cohort patients in physiological stage C were mainly those with univentricular heart and advanced heart failure, our findings are consistent with the profound immune abnormalities, which are typically described in this population, including low immunoglobulin levels and lymphopenia 19, 20 .Furthermore, it is interesting to note that despite multiple risk factors for severe disease in case of viral exposure, 14%of patients with no history of known SARS-COV2 infection had positive nucleocapsid antibodies, suggesting mildly symptomatic disease.

Although the speed and impact of the pandemic justifies a proactive approach in at-risk population, ACHD patients and their caregivers need to make a decision on accepting vaccination based on limited evidence and a hesitant attitude towards COVID-19 vaccination may be expected in some cases 21, 22 . Since the beginning of the national vaccination campaign, ACHD patients followed at our centre were strongly encouraged to undergo COVID-19 vaccination during both in person and remote consultations 23 . In our study population, only a small minority of patients rejected the vaccine. This J o u r n a l P r e -p r o o f is likely the effect of the health-related education received since childhood. Moreover, data collected during the clinic highlightened the crucial role of the ACHD team in the patients' vaccination journey.

Vulnerable patients might be more willing to undergo COVID-19 vaccination in a "safe" setting with specialized personnel and ACHD expertise. Therefore,patients' education including discussion on the importance of the vaccination during the clinical consultation as well as COVID-19 vaccines administration in situ at the ACHD tertiary centre, where patients are and feel cared for, may improve vaccine acceptance.

Our study is limited by the single-centre design, limited sample size and highly heterogeneous study population. However, our data reflect the case mix of the most vulnerable patients attending our ACHD centre. Other limitations include the lack of cellular immunity and neutralization assay testing.

However, anti-spike titers were shown to be strongly correlated to neutralization levels 24 

Our study provides the first real-world evidence of COVID-19 vaccines safety and immunogenicity in ACHD patients. Vaccine administration was low risk, and avoidance of vaccination based on fears of vulnerability due to underlying heart disease seems unjustified from this experience. ACHD patients with advanced physiological stage may develop lower antibody response regardless of previous viral exposure. Furthermore, the ACHD team may play a key role in vaccine acceptance in 

Accessed on

Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis

ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of

Cardiology Solution Set Oversight Committee

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

AHA/ACC Guideline for the Management of

Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

COVID-19 in Adults With Congenital Heart Disease

Board of the Italian Society of Pediatric Cardiology

Vaccine Priority Access for Adults and Children with Congenital Heart Disease: A Statement of the Italian Society of Pediatric Cardiology

Congenital Heart Disease Working Group of the

Tolerability, and Immunogenicity of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. medRxiv

Myocarditis after SARS-CoV-2 Vaccination: A Vaccineinduced Reaction?

Myopericarditis in a Previously Healthy Adolescent Male Following COVID-19 Vaccination: A Case Report

Cerebral Venous Sinus Thrombosis in the US Population, after Adenovirus-based SARS-CoV-2 Vaccination, and After COVID-19

Epub ahead of print

Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase

Epub ahead of print

Antibody Response to the BNT162b2 mRNA COVID-19

Vaccine in Subjects with Prior SARS-CoV-2 Infection. Viruses

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study

Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease

Evaluation and Management of the Child and Adult With Fontan Circulation: A Scientific Statement From the American Heart Association

Vaccine hesitancy: the next challenge in the fight against COVID-19

COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II

Caring for adults with CHD in the era of coronavirus disease 2019 pandemic: early experience in an Italian tertiary centre

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses